Insiders who reported open-market trades in the last 12 months at the companies Justin B. Klee files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Joshua B. Cohen - $3.60M in AMLX purchases and sales in the last 12 months
Gina Mazzariello - $1.05M in AMLX purchases and sales in the last 12 months
George M. Milne Jr. - $831K in AMLX purchases and sales in the last 12 months
James M. Frates - $554K in AMLX purchases and sales in the last 12 months
Justin B. Klee is a corporate insider, tracked as Co-Chief Executive Officer, Director of Amylyx Pharmaceuticals, Inc. (AMLX). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Justin B. Klee submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Justin B. Klee been buying or selling stock?
Recorded transactions: 0 open-market purchases and 10 open-market sales ($4.09M) across all tracked filings.
Justin B. Klee is Co-Chief Executive Officer, Director of Amylyx Pharmaceuticals, Inc. (AMLX). 10 SEC Form 4 filings on record going back to 2024, most recently on 14 September 2026. Most recent open-market trade: sold $48K of AMLX on 14 September 2026. Lifetime open-market sales: $4.09M.
Recent transactions
15
The latest 15 SEC Form 4 transactions reported by Justin B. Klee.
InsiderAlpha's records for Justin B. Klee go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
